President Trump has tapped Dr. Heidi Overton, his deputy assistant for domestic policy, to be the next FDA commissioner, and the move signals a clear shift toward America First health priorities. Overton is a physician with a track record inside this administration on vaccines, biosecurity and conservative health policy. Her nomination brings a pro-life stance and experience from the White House and the America First Policy Institute to an agency that will be central on drug access, public health responses and regulatory oversight.
Trump praised Overton publicly, calling her a “ROCKSTAR” and insisting she will “continue putting AMERICA FIRST, and creating a HEALTHY AMERICA.” He pointed to her direct work alongside senior officials, quoting that “She has worked directly with Secretary Kennedy, Dr. Oz, and team, to deliver on the MOST TRANSFORMATIVE Health Agenda in History. She is known to take on the HARDEST issues, and bring me solutions that work best for the Country,” as evidence she can lead the FDA. The tone of the announcement was unapologetically bold and meant to reassure conservatives that priorities will shift toward family-centered and innovation-friendly policies.
In her current post Overton regularly briefs the president on health matters and helped shape an executive order that aimed to alter pediatric vaccine recommendations. That directive proposed narrowing routine childhood immunizations and spacing them out, while removing a federal push for minors to receive the COVID-19 vaccine. The changes were framed as returning decision-making power to parents and letting states tailor schedules rather than following a one-size-fits-all federal list.
Overton urged so-called blue states to consider the administration’s “gold standard” recommendations as an alternative, even as doctors voiced concerns. The pitch was political as much as it was medical: push for clearer parental authority and offer a conservative path on public health guidance. Her willingness to press the point, despite professional resistance, is part of why the White House sees her as a change agent.
At the Oval Office signing for that vaccine order, Secretary Kennedy underscored his confidence in her, saying “Heidi is ‘ALWAYS RIGHT,’ Secretary Kennedy recently said in the Oval Office!” Trump followed by arguing that “We need her leadership at the FDA now to ensure that the U.S. remains the WORLD LEADER for Scientific Discovery and CURES.” Those lines make it clear the administration intends to recenter the FDA around conservative priorities while promoting innovation and domestic leadership in research.
If confirmed, Overton would succeed Marty Makary, who left the post after disagreements with critics over several prominent FDA decisions. The transition also comes after reports that acting FDA Commissioner Kyle Diamantas was not interested in taking the job permanently. That context frames this nomination as not just personnel change but a deliberate policy reset at an agency that touches daily life through medicine, food safety and emerging therapies.
Overton has been outspoken about abortion policy, and that stance will matter because the FDA regulates abortion medication, including Mifepristone. In a February 2023 policy brief she wrote, “Abortion is corrosive to children, women, and society broadly because it devalues and extinguishes innocent human life. Unfortunately, federal policymakers have recently expanded access to abortion pills, also called chemical abortions, which are far more dangerous to women, enabling rapid access to abortion.” Those lines leave no doubt where she stands and how she might approach the FDA’s role in drug approvals and access.
Since Roe v. Wade was overturned in June 2022, medication abortion has become a more prominent option nationwide, and that trend places additional focus on FDA oversight of pill distribution, labeling and telehealth pathways. Conservatives argue for tighter review and more explicit safeguards, while opponents worry about access limits. Nomination of a commissioner who has written so directly on the topic ensures these debates will take place squarely inside the agency.
The FDA will also face immediate public health challenges, including a multistate Cyclospora outbreak that requires swift coordination on food safety and testing. A commissioner needs to be ready for crises that span inspection, lab work and communications with states and industry. Overton’s entry into the role would come with that practical, urgent work on the desk from day one.
Before returning to the White House this time, Overton spent a stint as vice chair and chief policy officer at the America First Policy Institute and served in the first Trump administration. Her career mixes government experience, conservative policy advocacy and a medical background, which is precisely the profile this administration favors for regulatory leadership. Expect confirmation hearings to highlight those credentials while testing how she plans to balance conservative priorities with the technical demands of running the FDA.
